Anthony Wing-Hung Chan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3243478/publications.pdf Version: 2024-02-01

		3334	7745
407	27,821	91	150
papers	citations	h-index	g-index
415	415	415	25832
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology, 2010, 51, 454-462.	7.3	1,052
2	Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut, 2010, 59, 969-974.	12.1	538
3	Clinical Scoring System to Predict Hepatocellular Carcinoma in Chronic Hepatitis B Carriers. Journal of Clinical Oncology, 2010, 28, 1660-1665.	1.6	424
4	Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut, 2012, 61, 409-415.	12.1	423
5	Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology, 2013, 58, 1537-1547.	7.3	408
6	Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. Journal of Hepatology, 2015, 62, 956-967.	3.7	398
7	Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016, 65, 1359-1368.	12.1	386
8	Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites. Gut, 2021, 70, 761-774.	12.1	382
9	Alanine aminotransferaseâ€based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. Journal of Viral Hepatitis, 2009, 16, 36-44.	2.0	363
10	Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. Journal of Hepatology, 2018, 69, 1284-1293.	3.7	360
11	Asia–Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017—Part 1: Definition, risk factors and assessment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 70-85.	2.8	358
12	<i>MET</i> Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis. Clinical Cancer Research, 2016, 22, 3048-3056.	7.0	352
13	RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg. Science Translational Medicine, 2017, 9, .	12.4	343
14	Serum Hepatitis B Surface Antigen Quantitation Can Reflect Hepatitis B Virus in the Liver and Predict Treatment Response. Clinical Gastroenterology and Hepatology, 2007, 5, 1462-1468.	4.4	320
15	Peptostreptococcus anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology, 2017, 152, 1419-1433.e5.	1.3	308
16	Liver Stiffness Measurement Using XL Probe in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2012, 107, 1862-1871.	0.4	292
17	Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nature Microbiology, 2019, 4, 2319-2330.	13.3	281
18	Hepatitis B surface antigen quantification: Why and how to use it in 2011 – A core group report. Journal of Hepatology, 2011, 55, 1121-1131.	3.7	280

#	Article	IF	CITATIONS
19	High Viral Load and Hepatitis B Virus Subgenotype Ce Are Associated With Increased Risk of Hepatocellular Carcinoma. Journal of Clinical Oncology, 2008, 26, 177-182.	1.6	278
20	Quantitative Elastography of Liver Fibrosis and Spleen Stiffness in Chronic Hepatitis B Carriers: Comparison of Shear-Wave Elastography and Transient Elastography with Liver Biopsy Correlation. Radiology, 2013, 269, 910-918.	7.3	267
21	The role of quantitative hepatitis B surface antigen revisited. Journal of Hepatology, 2017, 66, 398-411.	3.7	267
22	Molecular Characterization of the Fecal Microbiota in Patients with Nonalcoholic Steatohepatitis – A Longitudinal Study. PLoS ONE, 2013, 8, e62885.	2.5	266
23	Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients. Hepatology, 2017, 65, 54-64.	7.3	260
24	Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial. Journal of Hepatology, 2013, 59, 536-542.	3.7	254
25	Viral-Human Chimeric Transcript Predisposes Risk to Liver Cancer Development and Progression. Cancer Cell, 2014, 25, 335-349.	16.8	254
26	Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology, 2013, 12, 256-262.	1.5	252
27	A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-α2b and Lamivudine with Lamivudine Alone. Annals of Internal Medicine, 2005, 142, 240.	3.9	248
28	Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut, 2011, 60, 1721-1727.	12.1	248
29	Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy. American Journal of Gastroenterology, 2015, 110, 1306-1314.	0.4	240
30	Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B. Journal of Hepatology, 2014, 60, 339-345.	3.7	227
31	Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations. Nature Communications, 2017, 8, 14121.	12.8	227
32	A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology, 2010, 52, 1232-1241.	7.3	226
33	Yes-Associated Protein 1 Exhibits Oncogenic Property in Gastric Cancer and Its Nuclear Accumulation Associates with Poor Prognosis. Clinical Cancer Research, 2011, 17, 2130-2139.	7.0	224
34	MiR-222 Overexpression Confers Cell Migratory Advantages in Hepatocellular Carcinoma through Enhancing AKT Signaling. Clinical Cancer Research, 2010, 16, 867-875.	7.0	221
35	High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut, 2011, 60, 829-836.	12.1	219
36	Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan®. Journal of Hepatology, 2012, 56, 833-839.	3.7	218

#	Article	IF	CITATIONS
37	Prognostic Nutritional Index (PNI) Predicts Tumor Recurrence of Very Early/Early Stage Hepatocellular Carcinoma After Surgical Resection. Annals of Surgical Oncology, 2015, 22, 4138-4148.	1.5	206
38	Identification of Chronic Hepatitis B Patients without Significant Liver Fibrosis by a Simple Noninvasive Predictive Model. American Journal of Gastroenterology, 2005, 100, 616-623.	0.4	200
39	Hepatocellular Carcinoma and Hepatitis B Virus. Seminars in Liver Disease, 2006, 26, 153-161.	3.6	198
40	Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut, 2009, 58, 111-117.	12.1	198
41	Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. Journal of Hepatology, 2012, 56, 1363-1370.	3.7	198
42	Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. Journal of Hepatology, 2018, 69, 1349-1356.	3.7	198
43	High serum interleukinâ€6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. International Journal of Cancer, 2009, 124, 2766-2770.	5.1	197
44	Hepatitis B virus infection and fatty liver in the general population. Journal of Hepatology, 2012, 56, 533-540.	3.7	196
45	Fatty Pancreas, Insulin Resistance, and β-Cell Function: A Population Study Using Fat-Water Magnetic Resonance Imaging. American Journal of Gastroenterology, 2014, 109, 589-597.	0.4	194
46	Sirtuin 1 Is Upregulated in a Subset of Hepatocellular Carcinomas where It Is Essential for Telomere Maintenance and Tumor Cell Growth. Cancer Research, 2011, 71, 4138-4149.	0.9	189
47	Metabolic and Adipokine Profile of Chinese Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1154-1161.	4.4	181
48	SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology, 2013, 57, 2287-2298.	7.3	179
49	Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology, 2017, 65, 1145-1155.	7.3	177
50	Modulation of LMP2A Expression by a Newly Identified Epstein-Barr Virus-Encoded MicroRNA miR-BART22. Neoplasia, 2009, 11, 1174-IN17.	5.3	176
51	HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. Journal of Hepatology, 2019, 70, 361-370.	3.7	173
52	Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group. Journal of Clinical Oncology, 2012, 30, 3361-3367.	1.6	167
53	Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma. Journal of Hepatology, 2013, 58, 1165-1173.	3.7	160
54	Tenofovir Is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. Gastroenterology, 2020, 158, 215-225.e6.	1.3	156

#	Article	IF	CITATIONS
55	Pathogenesis and novel treatment options for non-alcoholic steatohepatitis. The Lancet Gastroenterology and Hepatology, 2016, 1, 56-67.	8.1	152
56	Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 667-676.	2.8	152
57	Controlled attenuation parameter for the diagnosis of steatosis in nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 848-855.	2.8	151
58	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. British Journal of Cancer, 2016, 114, 744-750.	6.4	150
59	Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. Journal of Hepatology, 2015, 62, 182-189.	3.7	147
60	Assessment of Fibrosis by Transient Elastography Compared With Liver Biopsy and Morphometry in Chronic Liver Diseases. Clinical Gastroenterology and Hepatology, 2008, 6, 1027-1035.	4.4	143
61	Management of hepatocellular carcinoma with portal vein tumor thrombosis: Review and update at 2016. World Journal of Gastroenterology, 2016, 22, 7289.	3.3	138
62	Hepatoma-intrinsic CCRK inhibition diminishes myeloid-derived suppressor cell immunosuppression and enhances immune-checkpoint blockade efficacy. Gut, 2018, 67, 931-944.	12.1	138
63	"Interchangeability―of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy. Modern Pathology, 2020, 33, 4-17.	5.5	135
64	Serial combination of nonâ€invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with <scp>NAFLD</scp> . Alimentary Pharmacology and Therapeutics, 2017, 46, 617-627.	3.7	134
65	Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. American Journal of Gastroenterology, 2002, 97, 406-412.	0.4	131
66	Hepatitis B Virus Genotype C Takes a More Aggressive Disease Course Than Hepatitis B Virus Genotype B in Hepatitis B e Antigen-Positive Patients. Journal of Clinical Microbiology, 2003, 41, 1277-1279.	3.9	127
67	<i><scp>PNPLA</scp>3</i> gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 139-146.	2.8	125
68	miR-375 is involved in Hippo pathway by targeting YAP1/TEAD4-CTGF axis in gastric carcinogenesis. Cell Death and Disease, 2018, 9, 92.	6.3	125
69	Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas. Gastroenterology, 2019, 157, 1630-1645.e6.	1.3	123
70	Liver injury is independently associated with adverse clinical outcomes in patients with COVID-19. Gut, 2021, 70, 733-742.	12.1	121
71	Impact of the New Definition of Metabolic Associated Fatty Liver Disease on the Epidemiology of the Disease. Clinical Gastroenterology and Hepatology, 2021, 19, 2161-2171.e5.	4.4	119
72	Renal Outcome in Type 2 Diabetic Patients With or Without Coexisting Nondiabetic Nephropathies. Diabetes Care, 2002, 25, 900-905.	8.6	118

#	Article	IF	CITATIONS
73	The Asia–Pacific Working Party on Nonâ€alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 86-98.	2.8	117
74	Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. Gut, 2020, 69, 365-379.	12.1	117
75	Wnt/β-Catenin activates MiR-183/96/182 expression in hepatocellular carcinoma that promotes cell invasion. Cancer Letters, 2015, 362, 97-105.	7.2	114
76	Coincidental metabolic syndrome increases the risk of liver fibrosis progression in patients with chronic hepatitis B – a prospective cohort study with paired transient elastography examinations. Alimentary Pharmacology and Therapeutics, 2014, 39, 883-893.	3.7	113
77	Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut, 2019, 68, 2057-2064.	12.1	113
78	Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology, 2017, 67, 902-908.	3.7	112
79	Development of a nonâ€invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2010, 31, 1095-1103.	3.7	110
80	Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen–Negative Chronic Hepatitis B Patients. Journal of Infectious Diseases, 2011, 204, 408-414.	4.0	110
81	Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter. Journal of Hepatology, 2017, 67, 577-584.	3.7	110
82	Metabolic and histological features of nonâ€alcoholic fatty liver disease patients with different serum alanine aminotransferase levels. Alimentary Pharmacology and Therapeutics, 2009, 29, 387-396.	3.7	108
83	Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 1002-1007.	2.8	104
84	Integration of albumin–bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1300-1306.	2.8	103
85	Validation of the NAFLD Fibrosis Score in a Chinese Population With Low Prevalence of Advanced Fibrosis. American Journal of Gastroenterology, 2008, 103, ???-???.	0.4	101
86	Longâ€ŧerm clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: A prospective cohort study. Hepatology, 2016, 63, 754-763.	7.3	101
87	Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology, 2010, 51, 1945-1953.	7.3	100
88	Frequent hypermethylation of promoter region of <i>RASSF1A</i> in tumor tissues and voided urine of urinary bladder cancer patients. International Journal of Cancer, 2003, 104, 611-616.	5.1	97
89	Liver Stiffness Measurement by Transient Elastography as a Predictor on Posthepatectomy Outcomes. Annals of Surgery, 2013, 257, 922-928.	4.2	96
90	Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC)- a correlative study to explore potential biomarkers for response. BMC Cancer, 2015, 15, 395.	2.6	96

#	Article	IF	CITATIONS
91	<i><scp>PNPLA</scp>3</i> gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Alimentary Pharmacology and Therapeutics, 2014, 39, 532-539.	3.7	95
92	New simple prognostic score for primary biliary cirrhosis: Albuminâ€bilirubin score. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1391-1396.	2.8	95
93	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Responseâ€Based Approach. Hepatology, 2020, 72, 198-212.	7.3	92
94	Prevalence of undiagnosed diabetes and postchallenge hyperglycaemia in Chinese patients with non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2006, 24, 1215-1222.	3.7	88
95	Epigenetic regulation of hepatocellular carcinoma in non-alcoholic fatty liver disease. Seminars in Cancer Biology, 2013, 23, 471-482.	9.6	88
96	MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis, 2012, 33, 1134-1141.	2.8	84
97	Evaluation of Alanine Transaminase and Hepatitis B Virus DNA to Predict Liver Cirrhosis in Hepatitis B e Antigen-Negative Chronic Hepatitis B Using Transient Elastography. American Journal of Gastroenterology, 2008, 103, 3071-3081.	0.4	83
98	Albumin-to-Alkaline Phosphatase Ratio: A Novel Prognostic Index for Hepatocellular Carcinoma. Disease Markers, 2015, 2015, 1-10.	1.3	83
99	Statin and the risk of hepatocellular carcinoma and death in a hospital-based hepatitis B-infected population: A propensity score landmark analysis. Journal of Hepatology, 2015, 63, 1190-1197.	3.7	83
100	Transient elastography. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1726-1731.	2.8	82
101	On-Treatment Monitoring of Liver Fibrosis with Transient Elastography in Chronic Hepatitis B Patients. Antiviral Therapy, 2011, 16, 165-172.	1.0	82
102	Management of patients with liver derangement during the COVID-19 pandemic: an Asia-Pacific position statement. The Lancet Gastroenterology and Hepatology, 2020, 5, 776-787.	8.1	82
103	Stathmin1 Plays Oncogenic Role and Is a Target of MicroRNA-223 in Gastric Cancer. PLoS ONE, 2012, 7, e33919.	2.5	82
104	Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Journal of Medical Virology, 2002, 68, 182-187.	5.0	81
105	A Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD) and Entecavir Treatment for Hepatitis B "e" Antigen-Positive Chronic Hepatitis B. Clinical Infectious Diseases, 2014, 59, 1714-1723.	5.8	79
106	Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. Journal of Hepatology, 2018, 69, 793-802.	3.7	79
107	Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology, 2005, 41, 1357-1364.	7.3	77
108	Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. Journal of Hepatology, 2018, 68, 63-72.	3.7	77

#	Article	IF	CITATIONS
109	Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. PLoS ONE, 2015, 10, e0139310.	2.5	77
110	Two-year Lamivudine treatment for Hepatitis B e Antigen-Negative Chronic Hepatitis B: A Double-Blind, Placebo-Controlled Trial. Antiviral Therapy, 2007, 12, 345-354.	1.0	76
111	Hepatitis B Virus Genotype C Is Associated With More Severe Liver Fibrosis Than Genotype B. Clinical Gastroenterology and Hepatology, 2009, 7, 1361-1366.	4.4	75
112	A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene, 2011, 30, 4464-4475.	5.9	75
113	Expression of stemness markers (<scp>CD</scp> 133 and Ep <scp>CAM</scp>) in prognostication of hepatocellular carcinoma. Histopathology, 2014, 64, 935-950.	2.9	75
114	Liver stiffness measurement predicts longâ€ŧerm survival and complications in nonâ€alcoholic fatty liver disease. Liver International, 2020, 40, 581-589.	3.9	75
115	Carboxyl-Terminal Truncated HBx Regulates a Distinct MicroRNA Transcription Program in Hepatocellular Carcinoma Development. PLoS ONE, 2011, 6, e22888.	2.5	73
116	Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. Journal of Hepatology, 2018, 68, 147-156.	3.7	72
117	Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?. British Journal of Cancer, 2018, 118, 248-257.	6.4	71
118	Clinical Factors Associated With Liver Stiffness in Hepatitis B e Antigen–Positive Chronic Hepatitis B Patients. Clinical Gastroenterology and Hepatology, 2009, 7, 227-233.	4.4	70
119	Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. Journal of Hepatology, 2014, 61, 708-709.	3.7	69
120	Putative tumour-suppressor gene DAB2is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer, 2010, 10, 253.	2.6	68
121	Chronic hepatitis B in Asia—new insights from the past decade. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 131-137.	2.8	68
122	Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant. Journal of Thoracic Oncology, 2013, 8, 883-891.	1.1	67
123	Prognostic Value of Controlled Attenuation Parameter by Transient Elastography. American Journal of Gastroenterology, 2017, 112, 1812-1823.	0.4	67
124	Lymphoepithelioma-like Hepatocellular Carcinoma. American Journal of Surgical Pathology, 2015, 39, 304-312.	3.7	66
125	An inflammatory-CCRK circuitry drives mTORC1-dependent metabolic and immunosuppressive reprogramming in obesity-associated hepatocellular carcinoma. Nature Communications, 2018, 9, 5214.	12.8	66
126	Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. International Journal of Cancer, 2003, 105, 204-209.	5.1	65

#	Article	IF	CITATIONS
127	Association Between Anthropometric Parameters and Measurements of Liver Stiffness by Transient Elastography. Clinical Gastroenterology and Hepatology, 2013, 11, 295-302.e3.	4.4	64
128	DNA of Erythroid Origin Is Present in Human Plasma and Informs the Types of Anemia. Clinical Chemistry, 2017, 63, 1614-1623.	3.2	63
129	Interaction of Adipokines and Hepatitis B Virus on Histological Liver Injury in the Chinese. American Journal of Gastroenterology, 2010, 105, 132-138.	0.4	62
130	Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBVâ€associated nasopharyngeal carcinoma. Journal of Pathology, 2012, 226, 471-481.	4.5	62
131	Assessment of nonâ€elcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology and Therapeutics, 2012, 36, 1057-1066.	3.7	61
132	Nonâ€invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 39, 197-208.	3.7	61
133	Characterization of rare transforming <i>KRAS</i> mutations in sporadic colorectal cancer. Cancer Biology and Therapy, 2014, 15, 768-776.	3.4	61
134	Genetic polymorphisms of adiponectin and tumor necrosis factorâ€alpha and nonalcoholic fatty liver disease in Chinese people. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 914-921.	2.8	60
135	Liver- and Colon-Specific DNA Methylation Markers in Plasma for Investigation of Colorectal Cancers with or without Liver Metastases. Clinical Chemistry, 2018, 64, 1239-1249.	3.2	60
136	Longâ€Read RNA Sequencing Identifies Alternative Splice Variants in Hepatocellular Carcinoma and Tumor‧pecific Isoforms. Hepatology, 2019, 70, 1011-1025.	7.3	60
137	Serial Transient Elastography Examinations to Monitor Patients With Type 2 Diabetes: A Prospective Cohort Study. Hepatology, 2020, 72, 1230-1241.	7.3	59
138	A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine, 2021, 13, .	12.4	59
139	Yin Yang 1 contributes to gastric carcinogenesis and its nuclear expression correlates with shorter survival in patients with early stage gastric adenocarcinoma. Journal of Translational Medicine, 2014, 12, 80.	4.4	58
140	Significant positive association of endotoxemia with histological severity in 237 patients with nonâ€alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 175-182.	3.7	58
141	RASAL2 promotes tumor progression through LATS2/YAP1 axis of hippo signaling pathway in colorectal cancer. Molecular Cancer, 2018, 17, 102.	19.2	58
142	Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2019, 114, 916-928.	0.4	57
143	Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 50, 1037-1048.	3.7	54
144	Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure. Journal of Hepatology, 2020, 72, 57-66.	3.7	54

#	Article	IF	CITATIONS
145	Adverse Effects of Vitamin D Deficiency on Outcomes of Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2015, 13, 783-790.e1.	4.4	52
146	<scp>E</scp> pstein– <scp>B</scp> arr virusâ€associated lymphoepitheliomaâ€like cholangiocarcinoma: a rare variant of intrahepatic cholangiocarcinoma with favourable outcome. Histopathology, 2014, 65, 674-683.	2.9	51
147	Liver Injury Is Common Among Chronic Abusers of Ketamine. Clinical Gastroenterology and Hepatology, 2014, 12, 1759-1762.e1.	4.4	51
148	Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. Journal of Thoracic Oncology, 2015, 10, 1292-1300.	1.1	51
149	Personalized therapy for hepatocellular carcinoma: Where are we now?. Cancer Treatment Reviews, 2016, 45, 77-86.	7.7	51
150	Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up. Clinical Gastroenterology and Hepatology, 2016, 14, 1481-1489.e5.	4.4	51
151	Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment. World Journal of Gastroenterology, 2003, 9, 2695.	3.3	50
152	Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. Journal of Hepatology, 2015, 63, 1086-1092.	3.7	49
153	Reassessing the accuracy of PACE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. Journal of Hepatology, 2020, 72, 847-854.	3.7	49
154	Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. Liver International, 2004, 24, 611-618.	3.9	48
155	Effects of Diabetes and Glycemic Control on Risk of Hepatocellular Carcinoma After Seroclearance of Hepatitis B Surface Antigen. Clinical Gastroenterology and Hepatology, 2018, 16, 765-773.e2.	4.4	48
156	Strong Immunohistochemical Expression of Vascular Endothelial Growth Factor Predicts Overall Survival in Head and Neck Squamous Cell Carcinoma. Annals of Surgical Oncology, 2007, 14, 3558-3565.	1.5	47
157	Applicability of albuminâ€bilirubinâ€based Japan integrated staging score in hepatitis Bâ€associated hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1766-1772.	2.8	47
158	Incorporating albumin–bilirubin grade into the cancer of the liver Italian program system for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 221-228.	2.8	47
159	Surrogate End Points and Long-Term Outcome in Patients With Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2009, 7, 1113-1120.	4.4	46
160	Yin Yang 1â€mediated epigenetic silencing of tumourâ€suppressive microRNAs activates nuclear factorâ€₽B in hepatocellular carcinoma. Journal of Pathology, 2016, 238, 651-664.	4.5	46
161	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients. PLoS ONE, 2013, 8, e54522.	2.5	46
162	Application of the combined FibroMeter vibrationâ€controlled transient elastography algorithm in Chinese patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1363-1369.	2.8	44

#	Article	IF	CITATIONS
163	EBVâ€encoded miRNAs target ATMâ€mediated response in nasopharyngeal carcinoma. Journal of Pathology, 2018, 244, 394-407.	4.5	44
164	Effect of age and disease on taste perception. Journal of Pain and Symptom Management, 2004, 28, 28-34.	1.2	43
165	Clinical utility of plasma Epsteinâ€Barr virus DNA and <i>ERCC1</i> single nucleotide polymorphism in nasopharyngeal carcinoma. Cancer, 2015, 121, 2720-2729.	4.1	43
166	A subset of breast cancer predisposes to brain metastasis. Medical Molecular Morphology, 2011, 44, 15-20.	1.0	42
167	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. Modern Pathology, 2018, 31, 1381-1390.	5.5	41
168	No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	41
169	Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVIDâ€19. Hepatology, 2021, 74, 1750-1765.	7.3	41
170	Angiotensinâ€converting enzyme inhibitors prevent liverâ€related events in nonalcoholic fatty liver disease. Hepatology, 2022, 76, 469-482.	7.3	41
171	Predictors of Treatment Response in Chronic Hepatitis B. Drugs, 2009, 69, 2167-2177.	10.9	40
172	The ATP-binding cassette transporter ABCF1 is a hepatic oncofetal protein that promotes chemoresistance, EMT and cancer stemness in hepatocellular carcinoma. Cancer Letters, 2019, 457, 98-109.	7.2	40
173	Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2020, 115, 867-875.	0.4	40
174	Artificial intelligence in prediction of nonâ€alcoholic fatty liver disease and fibrosis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 543-550.	2.8	40
175	Real-world risk score for hepatocellular carcinoma (RWS-HCC): a clinically practical risk predictor for HCC in chronic hepatitis B. Gut, 2016, 65, 887-888.	12.1	39
176	Liver stiffness measurement predicts highâ€grade postâ€hepatectomy liver failure: A prospective cohort study. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 506-514.	2.8	39
177	Chronic Hepatitis B Increases Liver-Related Mortality of Patients With Acute Hepatitis E: A Territorywide Cohort Study From 2000 to 2016. Clinical Infectious Diseases, 2018, 67, 1278-1284.	5.8	39
178	Systematic evaluation of circulating inflammatory markers for hepatocellular carcinoma. Liver International, 2017, 37, 280-289.	3.9	38
179	Modelling the economic and clinical burden of nonâ€alcoholic steatohepatitis in East Asia: Data from Hong Kong. Hepatology Research, 2020, 50, 1024-1031.	3.4	38
180	Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection. American Journal of Gastroenterology, 2021, 116, 1274-1283.	0.4	37

#	Article	IF	CITATIONS
181	Microwave ablation provides better survival than liver resection for hepatocellular carcinoma in patients with borderline liver function: application of ALBI score to patient selection. Hpb, 2018, 20, 546-554.	0.3	36
182	Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis <scp>B</scp> : A prospective cohort study with paired transient elastography examination. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1842-1848.	2.8	35
183	Endoscopic ultrasound-guided tissue acquisition with or without macroscopic on-site evaluation: randomized controlled trial. Endoscopy, 2020, 52, 856-863.	1.8	35
184	Characterization of early IgA nephropathy. American Journal of Kidney Diseases, 2000, 36, 703-708.	1.9	34
185	GEFâ€H1 overâ€expression in hepatocellular carcinoma promotes cell motility via activation of RhoA signalling. Journal of Pathology, 2012, 228, 575-585.	4.5	34
186	Non-alcoholic fatty liver disease: Spectral patterns observed from an in vivo phosphorus magnetic resonance spectroscopy study. Journal of Hepatology, 2014, 60, 809-815.	3.7	34
187	A review of the natural history of chronic hepatitis B in the era of transient elastography. Antiviral Therapy, 2009, 14, 489-499.	1.0	34
188	Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clinical Transplantation, 2004, 18, 295-300.	1.6	33
189	Transgenic cyclooxygenase-2 expression and high salt enhanced susceptibility to chemical-induced gastric cancer development in mice. Carcinogenesis, 2008, 29, 1648-1654.	2.8	33
190	Low Risk of Variceal Bleeding in Patients With Cirrhosis After Variceal Screening Stratified by Liver/Spleen Stiffness. Hepatology, 2019, 70, 971-981.	7.3	33
191	Association of genetic variations with NAFLD in lean individuals. Liver International, 2022, 42, 149-160.	3.9	33
192	Long-Term follow-up of Lamivudine Treatment in Patients with Severe Acute Exacerbation of Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B. Antiviral Therapy, 2008, 13, 571-579.	1.0	33
193	Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. , 2022, 19, 834-847.		33
194	The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis. Oncogene, 2017, 36, 4135-4149.	5.9	32
195	A prospective study on second-generation colon capsule endoscopy to detect mucosal lesions and disease activity in ulcerative colitis (with video). Gastrointestinal Endoscopy, 2017, 86, 1139-1146.e6.	1.0	32
196	Risk Factors for Active Liver Disease in Hbeag-Negative Chronic Hepatitis B Virus–Infected Patients. American Journal of Gastroenterology, 2000, 95, 3547-3551.	0.4	31
197	The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver International, 2011, 31, 1047-1053.	3.9	31
198	Measuring spleen stiffness to predict varices in chronic hepatitis B cirrhotic patients with or without receiving nonâ€selective betaâ€blockers. Journal of Digestive Diseases, 2016, 17, 538-546.	1.5	31

#	Article	IF	CITATIONS
199	Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment. Translational Gastroenterology and Hepatology, 2018, 3, 89-89.	3.0	30
200	A Retrospective Study on Clinical Features and Prognostic Factors of Biopsy-Proven Primary Biliary Cirrhosis in Chinese Patients. American Journal of Gastroenterology, 2005, 100, 2205-2211.	0.4	29
201	The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma. Journal of Pathology, 2017, 243, 418-430.	4.5	29
202	A hospital clinic-based survey on traditional Chinese medicine usage among chronic hepatitis B patients. Complementary Therapies in Medicine, 2005, 13, 175-182.	2.7	28
203	Non-invasive assessment of liver fibrosis with transient elastography (FibroScan®): applying the cut-offs of M probe to XL probe. Annals of Hepatology, 2013, 12, 402-412.	1.5	28
204	Targeted hepatitis <scp>C</scp> screening among exâ€injection drug users in the community. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 116-120.	2.8	28
205	Repeating measurements by transient elastography in nonâ€alcoholic fatty liver disease patients with high liver stiffness. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 241-248.	2.8	28
206	Development of a Novel Inflammation-Based Index for Hepatocellular Carcinoma. Liver Cancer, 2020, 9, 167-181.	7.7	28
207	Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong. PLoS ONE, 2015, 10, e0122406.	2.5	28
208	Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case ontrol Study. Hepatology Communications, 2022, 6, 679-691.	4.3	28
209	Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Nature Communications, 2022, 13, 156.	12.8	28
210	Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antiviral Therapy, 2007, 12, 345-53.	1.0	28
211	Long-Term Lamivudine Treatment is Associated with a Good Maintained Response in Severe Acute Exacerbation of Chronic Hbeag-Negative Hepatitis B. Antiviral Therapy, 2006, 11, 465-471.	1.0	28
212	Virological Response to Different Combination Regimes of Peginterferon α-2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B. Antiviral Therapy, 2007, 12, 815-823.	1.0	28
213	Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. American Journal of Gastroenterology, 2002, 97, 2629-2633.	0.4	27
214	Predictors of invasion in needle core biopsies of the breast with ductal carcinoma in situ. Modern Pathology, 2010, 23, 737-742.	5.5	27
215	Significance of hepatitis B virus genotypes and mutations in the development of hepatocellular carcinoma in Asia. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 8-12.	2.8	27
216	Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 484-491.	2.8	27

ANTHONY WING-HUNG CHAN

#	Article	IF	CITATIONS
217	Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy. Gut, 2020, 69, 1116-1126.	12.1	27
218	Improving transient elastography performance for detecting hepatitis B cirrhosis. Digestive and Liver Disease, 2012, 44, 61-66.	0.9	26
219	Dysregulated Lysine Acetyltransferase 2B Promotes Inflammatory Bowel Disease Pathogenesis Through Transcriptional Repression of Interleukin-10. Journal of Crohn's and Colitis, 2016, 10, 726-734.	1.3	26
220	Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores. Journal of Crohn's and Colitis, 2017, 11, 1071-1077.	1.3	26
221	Genomic landscape of lymphoepitheliomaâ€like hepatocellular carcinoma. Journal of Pathology, 2019, 249, 166-172.	4.5	26
222	Significantly Lower Case-fatality Ratio of Coronavirus Disease 2019 (COVID-19) than Severe Acute Respiratory Syndrome (SARS) in Hong Kong—A Territory-Wide Cohort Study. Clinical Infectious Diseases, 2021, 72, e466-e475.	5.8	26
223	Risk of Advanced Adenomas in Siblings of Individuals With Advanced Adenomas: A Cross-Sectional Study. Gastroenterology, 2016, 150, 608-616.	1.3	25
224	A Sequential Algorithm Combining ADAPT and Liver Stiffness Can Stage Metabolic-Associated Fatty Liver Disease in Hospital-Based and Primary Care Patients. American Journal of Gastroenterology, 2021, 116, 984-993.	0.4	25
225	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. Oncology Reports, 2005, 13, 937-41.	2.6	25
226	Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment. Clinical Gastroenterology and Hepatology, 2008, 6, 1022-1026.	4.4	24
227	Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 461-468.e2.	4.4	24
228	On-Treatment Improvement of MELD Score Reduces Death and Hepatic Events in Patients With Hepatitis B-Related Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1629-1638.	0.4	24
229	Clinical Study of Singleâ€Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. Hepatology, 2021, 74, 1795-1808.	7.3	24
230	Risk of liverâ€related events by age and diabetes duration in patients with diabetes and nonalcoholic fatty liver disease. Hepatology, 2022, 76, 1409-1422.	7.3	24
231	Phylogenetic, Virological, and Clinical Characteristics of Genotype C Hepatitis B Virus with TCC at Codon 15 of the Precore Region. Journal of Clinical Microbiology, 2006, 44, 681-687.	3.9	23
232	Treatment of nonâ€ e lcoholic steatohepatitis with <i><scp>P</scp>hyllanthus urinaria</i> : A randomized trial. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 57-62.	2.8	23
233	Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdominal Imaging, 2014, 39, 1241-1246.	2.0	23
234	Metabolic syndrome increases cardiovascular events but not hepatic events and death in patients with chronic hepatitis B. Hepatology, 2016, 64, 1507-1517.	7.3	23

#	Article	IF	CITATIONS
235	Cell cycle-related kinase reprograms the liver immune microenvironment to promote cancer metastasis. Cellular and Molecular Immunology, 2021, 18, 1005-1015.	10.5	23
236	Similarly low risk of hepatocellular carcinoma after either spontaneous or nucleos(t)ide analogueâ€induced hepatitis B surface antigen loss. Alimentary Pharmacology and Therapeutics, 2021, 53, 321-331.	3.7	23
237	Use of Hepatitis B Virus DNA Quantitation To Predict Hepatitis B e Antigen Reversion in Cases of Chronic Hepatitis B. Journal of Clinical Microbiology, 2003, 41, 4793-4795.	3.9	22
238	Evaluation of Impact of Serial Hepatitis B Virus DNA Levels on Development of Hepatocellular Carcinoma. Journal of Clinical Microbiology, 2009, 47, 1830-1836.	3.9	22
239	Reduced <i>CRYL1</i> expression in hepatocellular carcinoma confers cell growth advantages and correlates with adverse patient prognosis. Journal of Pathology, 2010, 220, 348-360.	4.5	22
240	Association of the POU class 2 homeobox 1 gene (POU2F1) with susceptibility to Type 2 diabetes in Chinese populations. Diabetic Medicine, 2010, 27, 1443-1449.	2.3	22
241	Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Annals of Hepatology, 2012, 11, 284-293.	1.5	22
242	Liver fibrosis progression in chronic hepatitis <scp>B</scp> patients positive for hepatitis <scp>B</scp> e antigen: A prospective cohort study with paired transient elastography examination. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 1762-1769.	2.8	22
243	A phase 2 study of the efficacy and biomarker on the combination of transarterial chemoembolization and axitinib in the treatment of inoperable hepatocellular carcinoma. Cancer, 2017, 123, 3977-3985.	4.1	22
244	Four-year Outcomes After Cessation of Tenofovir in Immune-tolerant Chronic Hepatitis B Patients. Journal of Clinical Gastroenterology, 2018, 52, 347-352.	2.2	22
245	International validation of the Chinese University Prognostic Index for staging of hepatocellular carcinoma: a joint United Kingdom and Hong Kong study. Chinese Journal of Cancer, 2014, 33, 481-91.	4.9	22
246	MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. Oncology Reports, 2014, 31, 2071-2078.	2.6	21
247	Steatotic hepatocellular carcinoma: a variant associated with metabolic factors and late tumour relapse. Histopathology, 2016, 69, 971-984.	2.9	21
248	Albumin-bilirubin grade predicts the outcomes of liver resection versus radiofrequency ablation for very early/early stage of hepatocellular carcinoma. Journal of the Royal College of Surgeons of Edinburgh, 2018, 16, 163-170.	1.8	21
249	Performance of Simple Fibrosis Scores in Nonobese Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2020, 18, 2843-2845.e2.	4.4	21
250	Metabolic syndrome delays <scp>HB</scp> eAg seroclearance in Chinese patients with hepatitis B. Alimentary Pharmacology and Therapeutics, 2014, 40, 716-726.	3.7	20
251	Evaluation of histological staging systems for primary biliary cirrhosis: correlation with clinical and biochemical factors and significance of pathological parameters in prognostication. Histopathology, 2014, 65, 174-186.	2.9	20
252	Epigenetic silencing of GDF1 disrupts SMAD signaling to reinforce gastric cancer development. Oncogene, 2016, 35, 2133-2144.	5.9	20

#	Article	IF	CITATIONS
253	Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. Clinical and Translational Gastroenterology, 2021, 12, e00324.	2.5	20
254	A phase II clinical study on the efficacy and predictive biomarker of pegylated recombinant arginase on hepatocellular carcinoma. Investigational New Drugs, 2021, 39, 1375-1382.	2.6	20
255	Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus–infected patients. American Journal of Gastroenterology, 2000, 95, 3547-3551.	0.4	19
256	In vivo appearances of gallbladder carcinoma under magnifying endoscopy and probe-based confocal laser endomicroscopy after endosonographic gallbladder drainage. Endoscopy, 2014, 46, E13-E14.	1.8	19
257	Changing scene in hepatitis B serology interpretation. British Journal of Hospital Medicine, 2002, 63, 16-19.	0.2	18
258	Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients. Digestive Diseases and Sciences, 2015, 60, 1448-1456.	2.3	18
259	Crossâ€sectional area of the median nerve at the wrist: Comparison of sonographic, MRI, and cadaveric measurements. Journal of Clinical Ultrasound, 2019, 47, 122-127.	0.8	18
260	Hepatic Decompensation in Cirrhotic Patients Receiving Antiviral Therapy for Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2021, 19, 1950-1958.e7.	4.4	18
261	Increasing antiviral treatment uptake improves survival in patients with HBV-related HCC. JHEP Reports, 2020, 2, 100152.	4.9	18
262	Laparoscopic Hepatectomy (with or without Robotic Assistance) versus Radiofrequency Ablation as a Minimally Invasive Treatment for Very Early-Stage or Early-Stage Hepatocellular Carcinoma. Digestive Surgery, 2020, 37, 65-71.	1.2	17
263	Thiazolidinediones reduce the risk of hepatocellular carcinoma and hepatic events in diabetic patients with chronic hepatitis B. Journal of Viral Hepatitis, 2020, 27, 904-914.	2.0	17
264	Promoter hypermethylation of Death-associated protein-kinase gene associated with advance stage gastric cancer. Oncology Reports, 0, , .	2.6	17
265	Second-Trimester Detection of Mowat-Wilson Syndrome Using Comparative Genomic Hybridization Microarray Testing. Obstetrics and Gynecology, 2010, 115, 462-465.	2.4	16
266	Correlation of biomarkers in head and neck squamous cell carcinoma. Otolaryngology - Head and Neck Surgery, 2010, 143, 795-800.	1.9	16
267	Realâ€life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1230-1233.	2.8	16
268	Increased expression of GATA zinc finger domain containing 1 through gene amplification promotes liver cancer by directly inducing phosphatase of regenerating liver 3. Hepatology, 2018, 67, 2302-2319.	7.3	16
269	Epstein-Barr Virus-Induced Epigenetic Pathogenesis of Viral-Associated Lymphoepithelioma-Like Carcinomas and Natural Killer/T-Cell Lymphomas. Pathogens, 2018, 7, 63.	2.8	16
270	A comparability study of immunohistochemical assays for PD-L1 expression in hepatocellular carcinoma. Modern Pathology, 2019, 32, 1646-1656.	5.5	16

#	Article	IF	CITATIONS
271	Unresolved issues of immune tolerance in chronic hepatitis B. Journal of Gastroenterology, 2020, 55, 383-389.	5.1	16
272	Risks of AKI and Major Adverse Clinical Outcomes in Patients with Severe Acute Respiratory Syndrome or Coronavirus Disease 2019. Journal of the American Society of Nephrology: JASN, 2021, 32, 961-971.	6.1	16
273	HER2 Expression Predicts Improved Survival in Patients with Cervical Node-Positive Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2009, 141, 467-473.	1.9	15
274	Multiple modulatory activities of Andrographis paniculata on immune responses and xenograft growth in esophageal cancer preclinical models. Phytomedicine, 2019, 60, 152886.	5.3	15
275	Progressive increase of genetic alteration in urinary bladder cancer by combined allelotyping analysis and comparative genomic hybridization. International Journal of Oncology, 2009, 34, 963-70.	3.3	14
276	Chronic Hepatitis B: A Treatment Update. Seminars in Liver Disease, 2013, 33, 122-129.	3.6	14
277	Targeting ribonucleotide reductase M2 subunit by small interfering RNA exerts anti-oncogenic effects in gastric adenocarcinoma. Oncology Reports, 2014, 31, 2579-2586.	2.6	14
278	Applicability of <scp>BALAD</scp> score in prognostication of hepatitis <scp>B</scp> â€related hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1529-1535.	2.8	14
279	Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 2019, 49, 1509-1517.	3.7	14
280	Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B. Clinical and Molecular Hepatology, 2021, 27, 499-509.	8.9	14
281	A review of the natural history of chronic hepatitis B in the era of transient elastography. Antiviral Therapy, 2009, 14, 489-99.	1.0	14
282	Granulin epithelin precursor promotes colorectal carcinogenesis by activating MARK/ERK pathway. Journal of Translational Medicine, 2018, 16, 150.	4.4	13
283	Change in treatment paradigm in people who previously injected drugs with chronic hepatitis C in the era of directâ€acting antiviral therapy. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 1641-1647.	2.8	13
284	Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion. Journal of Hepatology, 2022, 77, 410-423.	3.7	13
285	Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1843-1847.	1.5	12
286	Serum hepatitis B surface antigen kinetics in severe reactivation of hepatitis e antigen negative chronic hepatitis B patients receiving nucleos(t)ide analogues. Antiviral Therapy, 2013, 18, 979-986.	1.0	12
287	Noninvasive assessments of liver fibrosis with transient elastography and <scp>H</scp> ui index predict survival in patients with chronic hepatitis <scp>B</scp> . Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 582-590.	2.8	12
288	Virus and Host Testing to Manage Chronic Hepatitis B. Clinical Infectious Diseases, 2016, 62, S298-S305.	5.8	12

#	Article	IF	CITATIONS
289	EXOSC4 functions as a potential oncogene in development and progression of colorectal cancer. Molecular Carcinogenesis, 2018, 57, 1780-1791.	2.7	12
290	Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. European Journal of Internal Medicine, 2021, 84, 68-73.	2.2	12
291	A prospective 5-year study on the use of transient elastography to monitor the improvement of non-alcoholic fatty liver disease following bariatric surgery. Scientific Reports, 2021, 11, 5416.	3.3	12
292	U-shaped relationship between urea level and hepatic decompensation in chronic liver diseases. Clinical and Molecular Hepatology, 2022, 28, 77-90.	8.9	12
293	Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis. JHEP Reports, 2022, 4, 100441.	4.9	12
294	Antiviral therapy for chronic hepatitis B: Challenges in Hong Kong. Journal of Hepatology, 2009, 51, 1088-1090.	3.7	11
295	Primary perivascular epithelioid cell tumour (PEComa) of the urinary bladder. Pathology, 2011, 43, 746-749.	0.6	11
296	A concurrent primary hepatic MALT lymphoma and hepatocellular carcinoma. Pathology, 2015, 47, 178-181.	0.6	11
297	Cost Effectiveness of Response-Guided Therapy With Peginterferon in the Treatment of Chronic Hepatitis B. Clinical Gastroenterology and Hepatology, 2015, 13, 377-385.e5.	4.4	11
298	A Pancreatic Mass With Multiple Hepatic Lesions. Clinical Gastroenterology and Hepatology, 2015, 13, e3-e4.	4.4	11
299	Validating the ALBI grade: Its current and future use in HCC prognostication. Journal of Hepatology, 2017, 66, 661-663.	3.7	11
300	EBV–encoded miRNAs can sensitize nasopharyngeal carcinoma to chemotherapeutic drugs by targeting BRCA1. Journal of Cellular and Molecular Medicine, 2020, 24, 13523-13535.	3.6	11
301	Extramedullary Nasal Plasmacytoma — An Unusual Clinical Entity. Ear, Nose and Throat Journal, 1996, 75, 171-173.	0.8	10
302	Impact of diabetes mellitus and hepatitis B virus coinfection on patients with chronic hepatitis C: A territoryâ€wide cohort study. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 934-941.	2.8	10
303	Virtual multiplex immunohistochemistry: Application on cell block of effusion and aspiration cytology. Diagnostic Cytopathology, 2020, 48, 417-423.	1.0	10
304	SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. Open Forum Infectious Diseases, 2021, 8, ofab205.	0.9	10
305	Malignant pigmented clear cell epithelioid cell tumor (PEComa) in an adolescent boy with widespread metastases: a rare entity in this age group. Pediatric Radiology, 2011, 41, 1587-1590.	2.0	9
306	Novel therapeutic targets and predictive markers for hepatocellular carcinoma. Expert Opinion on Therapeutic Targets, 2015, 19, 973-983.	3.4	9

#	Article	IF	CITATIONS
307	Association Between Serum Folate Level and Toxicity of Capecitabine During Treatment for Colorectal Cancer. Oncologist, 2018, 23, 1436-1445.	3.7	9
308	Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data. Antiviral Therapy, 2019, 24, 133-140.	1.0	9
309	Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. Journal of Pathology, 2020, 251, 74-86.	4.5	9
310	Colonoscopy and Risk of Colorectal Cancer in Patients With Nonalcoholic Fatty Liver Disease: A Retrospective Territoryâ€Wide Cohort Study. Hepatology Communications, 2021, 5, 1212-1223.	4.3	9
311	Familial extrarenal Wilms tumor. Journal of Pediatric Surgery, 2007, 42, 1826-1830.	1.6	8
312	A sensitive and specific liquid chromatography–tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2409-2414.	2.3	8
313	EUS-guided alcohol injection of pancreatic neuroendocrine tumor. Gastrointestinal Endoscopy, 2015, 82, 167.	1.0	8
314	Long-term lamivudine treatment is associated with a good maintained response in severe acute exacerbation of chronic HBeAg-negative hepatitis B. Antiviral Therapy, 2006, 11, 465-71.	1.0	8
315	Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antiviral Therapy, 2007, 12, 815-23.	1.0	8
316	Antiviral Drug Resistance Testing in Patients with Chronic Hepatitis B. Digestive Diseases and Sciences, 2012, 57, 221-231.	2.3	7
317	Peginterferon therapy for chronic hepatitis B: one size fits all?. Gut, 2013, 62, 185-187.	12.1	7
318	An Uncommon Insertion Mutation in Exon 19 of EGFR Showed Stable Disease after TKI Treatment. Journal of Thoracic Oncology, 2013, 8, e107-e108.	1.1	7
319	Impact of <i><scp>IL28B</scp></i> and <i><scp>PNPLA3</scp></i> polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis <scp>C</scp> virus. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1040-1048.	2.8	7
320	Impact of Weight Loss During Chemotherapy in Chinese Patients with Unresectable Pancreatic Cancer. Nutrition and Cancer, 2019, 71, 954-970.	2.0	7
321	Endoscopic ultrasound of pancreatic lesions. Journal of Visualized Surgery, 2016, 2, 119-119.	0.2	6
322	No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. PLoS ONE, 2018, 13, e0199198.	2.5	6
323	Macromolecular proton fraction mapping based on spin″ock magnetic resonance imaging. Magnetic Resonance in Medicine, 2020, 84, 3157-3171.	3.0	6
324	High incidence of hepatocellular carcinoma and cirrhotic complications in patients with psychiatric illness: a territory-wide cohort study. BMC Gastroenterology, 2020, 20, 128.	2.0	6

#	Article	IF	CITATIONS
325	Liver stiffness measurement predicts short-term and long-term outcomes in patients with hepatocellular carcinoma after curative liver resection. Journal of the Royal College of Surgeons of Edinburgh, 2022, 20, 78-84.	1.8	6
326	EUS-guided transduodenal biliary drainage. Gastrointestinal Endoscopy, 2010, 72, 186-187.	1.0	5
327	Benign epithelioid schwannoma of intraparotid facial nerve. Pathology, 2011, 43, 280-282.	0.6	5
328	45 YEAR OLD MAN WITH A PINEAL REGION TUMOR FOR OVER 15 YEARS. Brain Pathology, 2012, 22, 255-258.	4.1	5
329	Irreversible Electroporation of the Femoral Neurovascular Bundle: Imaging and Histologic Evaluation in a Swine Model. Journal of Vascular and Interventional Radiology, 2015, 26, 1212-1220.e1.	0.5	5
330	Topical Application of Mesenchymal Stromal Cells Ameliorated Liver Parenchyma Damage After Ischemia-Reperfusion Injury in an Animal Model. Transplantation Direct, 2017, 3, e160.	1.6	5
331	Primary hepatic gastrointestinal stromal tumor presented with rupture. Hepatobiliary Surgery and Nutrition, 2017, 6, 65-66.	1.5	5
332	Genetic variation in ABCB5 associates with risk of hepatocellular carcinoma. Journal of Cellular and Molecular Medicine, 2020, 24, 10705-10713.	3.6	5
333	Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Seminars in Liver Disease, 2021, 41, 182-190.	3.6	5
334	Congenital systemic Langerhans cell histiocytosis presenting as hydrops fetalis. Acta Paediatrica, International Journal of Paediatrics, 2005, 94, 1843-1847.	1.5	5
335	Non-Hodgkin's Lymphoma of the Knee: A Case Report. Iranian Journal of Radiology, 2015, 12, e7583.	0.2	5
336	Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 1131-1138.	2.8	5
337	Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate. Journal of Medical Virology, 2022, 94, 4440-4448.	5.0	5
338	Is transient elastography inaccurate in chronic hepatitis B and non-alcoholic fatty liver disease?. Journal of Hepatology, 2011, 55, 497.	3.7	4
339	Should all patients with nonalcoholic fatty liver disease undergo oral glucose tolerance test?. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 419-420.	2.8	4
340	Treatment of hepatitis C virus infection in patients with CKD. Nature Reviews Nephrology, 2016, 12, 5-6.	9.6	4
341	Ablative Chemoembolization for Hepatocellular Carcinoma: A Prospective Phase I Case-Control Comparison with Conventional Chemoembolization. Radiology, 2018, 287, 340-348.	7.3	4
342	Novel biomarkers GEP/ABCB5 regulate response to adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma. Hepatobiliary and Pancreatic Diseases International, 2018, 17, 524-530.	1.3	4

#	Article	IF	CITATIONS
343	Updates of pancreatic neuroendocrine neoplasm in the 2017 World Health Organization classification. Surgical Practice, 2019, 23, 42-47.	0.2	4
344	Factors associated with improvement in MELD score after antiviral treatment in patients with chronic hepatitis B. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 1610-1618.	2.8	4
345	Reply:. Hepatology, 2009, 50, 2049-2050.	7.3	3
346	Responseâ€guided therapy by hepatitis B surface antigen level for peginterferon therapy: What is next?. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 420-421.	2.8	3
347	Mechanism and Natural Course of Tumor Involution in Hepatocellular Carcinoma Following Transarterial Ethanol Ablation. CardioVascular and Interventional Radiology, 2016, 39, 1136-1143.	2.0	3
348	Reply to: Correspondence concerning "Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resectionâ€: Journal of Hepatology, 2019, 70, 573-574.	3.7	3
349	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. Biomarkers in Disease, 2017, , 623-635.	0.1	3
350	Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B. Antiviral Therapy, 2008, 13, 1029-1037.	1.0	3
351	984 COMBINATION OF THE MEDIAN AND VARIABILITY OF LIVER STIFFNESS MEASUREMENTS BY TRANSIENT ELASTOGRAPHY IMPROVES THE ACCURACY OF DIAGNOSING ADVANCED FIBROSIS IN NONALCOHOLIC FATTY LIVER DISEASE. Journal of Hepatology, 2008, 48, S367.	3.7	2
352	Renal myxoid tumour of uncertain malignant potential. Pathology, 2011, 43, 287-289.	0.6	2
353	Two are better than one: noninvasive assessment of liver fibrosis in nonalcoholic fatty liver disease. Hepatology International, 2015, 9, 481-483.	4.2	2
354	HHV8 genotype study in an HIV+ patient with concurrent Kaposi sarcoma and extracavitary primary effusion lymphoma. Journal of Clinical Pathology, 2017, 70, 814-816.	2.0	2
355	Peptostreptococcus Anaerobius Induces Intracellular Cholesterol Biosynthesis in Colon Cells to Induce Proliferation and Causes Dysplasia in Mice. Gastroenterology, 2017, 152, S1010.	1.3	2
356	Towards finite oral antiviral treatment for chronic hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 260-262.	8.1	2
357	Reply. Hepatology, 2016, 64, 685-686.	7.3	1
358	Fecal Immunochemical Test Predicts Histological Healing in Ulcerative Colitis: A Prospective Study Using the Geboes Score and Nancy Index. Gastroenterology, 2017, 152, S209.	1.3	1
359	Serial combination of noninvasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with nonalcoholic fatty liver disease. Digestive and Liver Disease, 2017, 49, e2.	0.9	1
360	Impact of Non-alcoholic Fatty Liver Disease on Chronic Hepatitis B Infection. Current Hepatology Reports, 2017, 16, 97-104.	0.9	1

#	Article	IF	CITATIONS
361	IDDF2018-ABS-0107â€Efficacy and safety of TENOFOVIR ALAFENAMIDE (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of TENOFOVIR DISOPROXIL FUMARATE (TDF). , 2018, , .		1
362	PS-201-External validation in NAFLD cohorts of the FibroScan-based FAST score combining liver stiffness, controlled attenuation parameter and AST to identify patients with active NASH (NAS ≥ 4) and significant fibrosis (F ≥ 2). Journal of Hepatology, 2019, 70, e134-e135.	3.7	1
363	En bloc transdiaphragmatic lung resection for locally advanced hepatocellular carcinoma: a case report. Journal of Surgical Case Reports, 2020, 2020, rjaa084.	0.4	1
364	Letter to the Editor: Use of Pregenomic Hepatitis B Virus RNA and Hepatitis B Core–Related Antigen to Predict Cure of Hepatitis B Virus Infection. Hepatology, 2021, 73, 870-870.	7.3	1
365	Sodiumâ€glucose coâ€transporter 2 inhibitors reduce hepatic events in diabetic patients with chronic hepatitis B. GastroHep, 2021, 3, 261-269.	0.6	1
366	Single-nucleotide polymorphism (SNP) of excision repair cross complementation group 1 (ERCC1) in nasopharynx cancer (NPC): A companion biomarker study to Hong Kong NPC Study Group 0502 trial Journal of Clinical Oncology, 2014, 32, 6029-6029.	1.6	1
367	The association between serum folate level and toxicity of capecitabine Journal of Clinical Oncology, 2016, 34, 3566-3566.	1.6	1
368	A study on thromboembolism of patients with pancreatic cancer Journal of Clinical Oncology, 2017, 35, 262-262.	1.6	1
369	CD133 and EpCAM as Biomarkers in Liver Diseases. Biomarkers in Disease, 2017, , 349-372.	0.1	1
370	Abstract 4563: PD-L1 expression associated with treatment responses in colorectal cancer patients with XELOX/FOLFOX chemotherapy: Potential of checkpoint blockage and natural killer cell-based immunotherapy. , 2018, , .		1
371	Letter: systematic review with metaâ€analysis on the impact of functional cure on clinical outcomes in patients with chronic hepatitis B. Alimentary Pharmacology and Therapeutics, 2022, 55, 616-617.	3.7	1
372	Molecular virology and drug resistance in antiviral therapy of chronic hepatitis B. Current Hepatitis Reports, 2005, 4, 27-33.	0.3	0
373	Fine needle aspiration cytology of breast cancer in women aged 70 years and older. Pathology, 2008, 40, 573-579.	0.6	0
374	Metabolic syndrome and chronic hepatitis B: is the evidence enough?. Gut, 2010, 59, 277.1-277.	12.1	0
375	Case report and a review of the literature of two patients with gastric <scp>MALT</scp> oma and pulmonary metastasis. Surgical Practice, 2013, 17, 28-30.	0.2	0
376	Case of hepatocellular carcinoma with multicentric Castleman's disease. Surgical Practice, 2014, 18, 154-155.	0.2	0
377	A Rare Tumor of the Common Hepatic Duct Causing Biliary Obstruction. Clinical Gastroenterology and Hepatology, 2014, 12, e29-e30.	4.4	0
378	A Rare Cause of Protein-Losing Enteropathy. Clinical Gastroenterology and Hepatology, 2014, 12, e49-e50.	4.4	0

#	Article	IF	CITATIONS
379	Development of Serum DHCR24 Antibody as a Marker for Hepatocellular Carcinoma: The End of the Beginning. EBioMedicine, 2015, 2, 497-498.	6.1	0
380	Reply. Hepatology, 2016, 64, 1820-1821.	7.3	0
381	MET DNA Alterations in NSCLC—Reply. Clinical Cancer Research, 2016, 22, 3699-3699.	7.0	0
382	A Rare Cause of Ischemic Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, e109-e110.	4.4	0
383	Comments on "Proposal and validation of a new model to estimate survival for hepatocellular carcinoma patients― European Journal of Cancer, 2016, 68, 203-205.	2.8	Ο
384	Reply to: "Serum HBsAg kinetics in clinical prediction― Journal of Hepatology, 2017, 67, 193-194.	3.7	0
385	GATAD1 Promotes Hepatocellular Carcinogenesis through Directly Inducing PTP4A3 and Activating Akt Pathway. Gastroenterology, 2017, 152, S1182.	1.3	0
386	Non-invasive Assessment of Liver Disease. , 2018, , 163-179.		0
387	Reply to: "Risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearanceâ€. Journal of Hepatology, 2018, 68, 208-209.	3.7	0
388	IDDF2018-ABS-0058â€Early normalisation of alanine aminotransferase (alt) after nucleos(t)ide analogue treatment reduces the risk of hepatocellular carcinoma (hcc) in patients with chronic hepatitis b – a territory-wide study of 21,182 subjects. , 2018, , .		0
389	IDDF2018-ABS-0106â€Tenofovir alafenamide (taf) compared with tenofovir disoproxil fumarate (tdf) in patients with chronic hbv: week 96 efficacy and safety results in chinese patients enrolled in 2 global phase 3 studies. , 2018, , .		0
390	Reply to: "NAFLD and beneficial effects of lifestyle intervention: Defining the meat of the matter― Journal of Hepatology, 2019, 70, 1304.	3.7	0
391	IDDF2019-ABS-0199â€The risk of metabolic acidosis in diabetic patients with different severity of chronic hepatitis B-related cirrhosis and renal impairment. , 2019, , .		0
392	IDDF2019-ABS-0325â€Superior efficacy and long-term survival benefit of HDAC8 and PD-L1 co-blockade in liver cancer immunotherapy. , 2019, , .		0
393	IDDF2019-ABS-0174â€Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma. , 2019, , .		0
394	Reply to: "Hepatocellular carcinoma risk stratification in HBV cirrhosis: Time to turn the page― Journal of Hepatology, 2020, 73, 729-730.	3.7	0
395	Debate settled for elevated alanine aminotransferase in hepatitis B?. Lancet Infectious Diseases, The, 2021, 21, 750-751.	9.1	0
396	IDDF2021-ABS-0122â€No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients. , 2021, , .		0

#	Article	IF	CITATIONS
397	Abstract 4127: MiR-183/96/182 cluster confers cell motile advantages in hepatocellular carcinoma. , 2012, , .		0
398	Abstract 1245: Reactivation of growth/differentiation factor 1 contributes to the chemopreventive effect of 5-aza-2′deoxycytidine in gastric cancer. , 2014, , .		0
399	CD133 and EpCAM as Biomarkers in Liver Diseases. Exposure and Health, 2015, , 1-24.	4.9	0
400	A phase II clinical trial on combined axitinib and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC): Final results and evaluation of clinical predictor for response Journal of Clinical Oncology, 2015, 33, 4073-4073.	1.6	0
401	Alpha-Fetoprotein as a Biomarker in Hepatocellular Carcinoma: Focus on Its Role in Composition of Tumor Staging Systems and Monitoring of Treatment Response. Biomarkers in Disease, 2016, , 1-13.	0.1	0
402	Clinical Application, Performance, and Common Pitfalls of Ultrasound-guided Pleural Biopsy: Our Local Experience. Hong Kong Journal of Radiology, 0, , 103-110.	0.1	0
403	A novel and validated inflammation-integrated prognostic model for hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2017, 35, e15679-e15679.	1.6	0
404	Hepatic adverse events during treatment with immune checkpoint inhibitors (ICI) in cancer patients: A territory-wide patient cohort study Journal of Clinical Oncology, 2020, 38, 508-508.	1.6	0
405	IDDF2020-ABS-0200â€Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients. , 2020, , .		0
406	Recognising the clinically significant macrotrabecular massive variant of hepatocellular carcinoma. Singapore Medical Journal, 2022, , .	0.6	0
407	Use of Proton-Pump Inhibitor Is Not Associated with Adverse Clinical Outcomes in COVID-19 Patients: A Territory-Wide Cohort Study. GastroHep, 2022, 2022, 1-13.	0.6	0